ST. LOUIS and BERN, Switzerland, Nov. 10, 2020 (GLOBE NEWSWIRE) — Immunophotonics, Inc. announces the first patient treated in the phase 1b/2a clinical trial examining IP-001 in thermally ablated solid tumors. The trial, conducted in collaboration with the Swiss Group for Clinical Cancer Research (SAKK), will assess the safety, tolerability and anti-tumor activity of IP-001 administered intratumorally following tumor ablation.

“The initiation of this clinical trial marks a significant milestone for Immunophotonics. The trial will serve as a foundation in demonstrating the potential of IP-001 to ignite the immune system, transforming a routine tumor ablation into a systemic immunotherapy,” said Lu Alleruzzo, CEO of Immunophotonics. “IP-001 is the first of what is expected to be many novel agents and combinations that we bring into clinical development to help patients suffering from cancer.”

Prof. Markus Jörger, M.D., Ph.D., Coordinating Investigator of the trial commented, “IP-001 combines the promise of modern immunotherapy with the trend towards intratumoral treatment. SAKK is excited to bring this novel treatment to patients in desperate need for new innovative treatment options.”

Following the phase 1b all-comer portion of the trial, Immunophotonics intends to evaluate the safety and efficacy of IP-001, in conjunction with tumor ablation, in phase 2 cohorts of patients with specific types of cancer.

To read more, click here.